MwanzoABCL • NASDAQ
add
AbCellera Biologics Inc
$ 2.70
Baada ya Saa za Kazi:(1.11%)+0.030
$ 2.73
Imefungwa: 8 Nov, 20:00:00 GMT -5 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 2.72
Bei za siku
$ 2.62 - $ 2.75
Bei za mwaka
$ 2.34 - $ 6.05
Thamani ya kampuni katika soko
795.60M USD
Wastani wa hisa zilizouzwa
1.87M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 6.51M | -1.39% |
Matumizi ya uendeshaji wa biashara | 100.17M | 324.95% |
Mapato halisi | -51.11M | -78.63% |
Kiwango cha faida halisi | -785.42 | -81.16% |
Mapato kwa kila hisa | -0.17 | -70.00% |
EBITDA | -56.74M | -15.44% |
Asilimia ya kodi ya mapato | 18.40% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 643.14M | -18.16% |
Jumla ya mali | 1.39B | -7.89% |
Jumla ya dhima | 314.73M | -4.46% |
Jumla ya hisa | 1.08B | — |
hisa zilizosalia | 295.16M | — |
Uwiano wa bei na thamani | 0.75 | — |
Faida inayotokana na mali | -16.69% | — |
Faida inayotokana mtaji | -20.12% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -51.11M | -78.63% |
Pesa kutokana na shughuli | -28.88M | -27,147.17% |
Pesa kutokana na uwekezaji | 3.70M | 128.92% |
Pesa kutokana na ufadhili | 3.14M | -52.56% |
Mabadiliko halisi ya pesa taslimu | -21.67M | -195.86% |
Mtiririko huru wa pesa | -22.52M | 42.04% |
Kuhusu
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2012
Makao Makuu
Tovuti
Wafanyakazi
586
